Drugs / Gimistotug
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04215978 | Jan 2020 → Jan 2025 | head and neck squamous cell carcinoma, nasopharyngeal carcinoma, non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05661955 | Jan 2023 → May 2025 overdue | melanoma, renal cell carcinoma, urothelial carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06029127 | Oct 2023 → Dec 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05635708 | Mar 2023 → Dec 2025 overdue | non-small cell lung carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-25 | BeOne Medicines | Results BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio beonemedicines.com ↗
These results include data for BeiGene’s cornerstone therapies, BRUKINSA® (zanubrutinib) and tislelizumab, as well as early results for BeiGene’s OX40 agonist and BCL-2 inhibitor. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-05-25 | BeOne Medicines | BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio beonemedicines.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gimistotug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06029127 ↗ |
| Known as | BGB-A445 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04215978 ↗ |
| Action | Activate | “OX40 Agonist” NCT04215978 ↗ |
| Modality | Monoclonal antibody | “Anti OX40 Agonist Monoclonal Antibody BGB-A445” NCT04215978 ↗ |
| Route | Intravenous | “intravenous (IV) infusion of BGB-A445” NCT04215978 ↗ |